Citations

Showing 10 of 108119 citations.

A longitudinal investigation of Aβ, anxiety, depression, and mild cognitive impairment
Pink, Anna , Syrjanen, Jeremy A. , Vassilaki, Maria , Lowe, Val J. , Vemuri, Prashanthi , Christianson, Teresa J., Kremers, Walter K. , Jack, Clifford R. , Petersen, Ronald C. , Geda, Yonas E. , Krell-Roesch, Janina, Geda, Yonas E , Jack, Clifford R , Vemuri, Prashanthi , Kremers, Walter K , Krell‐Roesch, Janina , Stokin, Gorazd B. , Knopman, David S.

Mayo Clinic

Alzheimer's & Dementia | December 8, 2021 | Volume: 18 | Issue: 10 | Pages: 1824-1831

10.1002/alz.12504 | PMID 34877794 Get It

Abstract Introduction We investigated the longitudinal relationship between cortical amyloid deposition, anxiety, and depression and the risk of incident mild cognitive impairment (MCI). Methods We followed 1440 community‐dwelling, cognitively unimpaired individuals aged ≥ 50 years for a median of 5.5 years. Clinical anxiety and depression were assessed using Beck Anxiety and Depression Inventories (BAI, BDI‐II). Cortical amyloid beta (Aβ) was measured by Pittsburgh compound B positron emission tomography (PiB‐PET) and elevated deposition (PiB+) was defined as standardized uptake value ratio ≥ 1.48. We calculated Cox proportional hazards models with age as the time scale, adjusted for sex, education, and medical comorbidity. Results Cortical Aβ deposition (PiB+) independent of anxiety (BAI ≥ 10) or depression (BDI‐II ≥ 13) increased the risk of MCI. There was a significant additive interaction between PiB+ and anxiety (joint effect hazard ratio 6.77; 95% confidence interval 3.58–12.79; P = .031) that is, being PiB+ and having anxiety further amplified the risk of MCI. Discussion Anxiety modified the association between PiB+ and incident MCI.
Medulläres Schilddrüsenkarzinom
Kroiß, Matthias , Koehler, Viktoria Florentine , Spitzweg, Christine , Kroiss, Matthias

Mayo Clinic

DMW - Deutsche Medizinische Wochenschrift | December 8, 2021 | Volume: 146 | Issue: 23 | Pages: e114-e114

10.1055/a-1708-7360 | PMID 34875710 Get It

Neuroimaging phenotypes of CSF1R‐related leukoencephalopathy: Systematic review, meta‐analysis, and imaging recommendations
Mickeviciute, Goda‐Camille , Valiuskyte, Monika , Plattén, Michael , Wszołek, Zbigniew K. , Andersen, Oluf , Karrenbauer, Virginija Danylaité , Ineichen, Benjamin Victor , Danylaité Karrenbauer, Virginija , Ineichen, Benjamin V , Granberg, Tobias , Wszolek, Z.K.

Mayo Clinic

Journal of Internal Medicine | December 7, 2021 | Volume: 291 | Issue: 3 | Pages: 269-282

10.1111/joim.13420 | PMID 34875121 Get It

AbstractColony‐stimulating factor 1 receptor (CSF1R)‐related leukoencephalopathy is a rare but fatal microgliopathy. The diagnosis is often delayed due to multifaceted symptoms that can mimic several other neurological disorders. Imaging provides diagnostic clues that help identify cases. The objective of this study was to integrate the literature on neuroimaging phenotypes of CSF1R‐related leukoencephalopathy. A systematic review and meta‐analysis were performed for neuroimaging findings of CSF1R‐related leukoencephalopathy via PubMed, Web of Science, and Embase on 25 August 2021. The search included cases with confirmed CSF1R mutations reported under the previous terms hereditary diffuse leukoencephalopathy with spheroids, pigmentary orthochromatic leukodystrophy, and adult‐onset leukoencephalopathy with axonal spheroids and pigmented glia. In 78 studies providing neuroimaging data, 195 cases were identified carrying CSF1R mutations in 14 exons and five introns. Women had a statistically significant earlier age of onset (p = 0.041, 40 vs 43 years). Mean delay between symptom onset and neuroimaging was 2.3 years. Main magnetic resonance imaging (MRI) findings were frontoparietal white matter lesions, callosal thinning, and foci of restricted diffusion. The hallmark computed tomography (CT) finding was white matter calcifications. Widespread cerebral hypometabolism and hypoperfusion were reported using positron emission tomography and single‐photon emission computed tomography. In conclusion, CSF1R‐related leukoencephalopathy is associated with progressive white matter lesions and brain atrophy that can resemble other neurodegenerative/‐inflammatory disorders. However, long‐lasting diffusion restriction and parenchymal calcifications are more specific findings that can aid the differential diagnosis. Native brain CT and brain MRI (with and without a contrast agent) are recommended with proposed protocols and pictorial examples are provided.
CORR Insights®: What Is the Impact of Automated Synovial Cell Counting on Different Aseptic Causes and Periprosthetic Conditions Associated With Revision THA?
Schwartz, Adam J. , Schwartz, Adam J.

Mayo Clinic

Clinical Orthopaedics & Related Research | December 7, 2021 | Volume: 480 | Issue: 5 | Pages: 915-917

10.1097/corr.0000000000002086 | PMID 34874342 Get It

Clinical Update on Novel Lipid-Lowering Therapies to Reduce Cardiovascular Risk
Ray, Kausik K. , Wright, R. Scott , Ray, Kausik K

Mayo Clinic

JAMA | December 7, 2021 | Volume: 326 | Issue: 21 | Pages: 2205

10.1001/jama.2021.17992 | PMID 34874424 Get It

An International Multicenter Cohort Study on β-Blockers for the Treatment of Symptomatic Children With Catecholaminergic Polymorphic Ventricular Tachycardia
Peltenburg, Puck J. , Kallas, Dania , Bos, J. Martijn , Lieve, Krystien V.V. , Franciosi, Sonia , Roston, Thomas M. , Denjoy, Isabelle , Sorensen, Katrina B. , Ohno, Seiko , Rosés‐Noguer, Ferran , Aiba, Takeshi , Maltret, Alice , Atallah, Joseph , Giudicessi, John R. , Tanck, Michael W.T. , Kato, Koichi , Barc, Julien , Borggrefe, Martin, Behr, Elijah R. , Tfelt‐Hansen, Jacob , Zorio, Esther , Swan, Heikki, Kammeraad, Janneke A.E. , Sacher, Frédéric , Roberts, Jason D. , Berg, Maarten P. van den , Robyns, Tomas , Tavačová, Terézia , Semsarian, Christopher , Till, Jan , Horie, Minoru , Ackerman, Michael J. , Sanatani, Shubhayan , Wilde, Arthur A.M. , Bos, Johan M , LaPage, Martin J , Atallah, Joseph , Giudicessi, J R , Clur, Sally-Ann B , Tanck, Michael , Extramiana, Fabrice , Kato, Koichi , Barc, Julien , Behr, Elijah Raphael , Tfelt-Hansen, Jacob , Zorio, Esther , Krahn, Andrew D , Davis, Andrew , Sacher, Frederic , Schwartz, Peter J. , Roberts, Jason D , Skinner, Jonathan R , van den Berg, Maarten P , Kannankeril, Prince J , Drago, Fabrizio , Robyns, Tomas , Haugaa, Kristina , Tavacova, Terezia , Semsarian, Christopher , Probst, Vincent , Brugada, Ramón , Shimizu, Wataru , Horie, Minoru , Leenhardt, Antoine , Ackerman, Michael J , Sanatani, Shubhayan , Wilde, Arthur A M , Denjoy, Isabelle , Rosés-Noguer, Ferran , Lieve, Krystien V , Peltenburg, Puck J , Ohno, Seiko , Aiba, Takeshi , Clur, Sally‐Ann B. , Blom, Nico A. , Sarquella-Brugada, Georgia , Krahn, Andrew D. , Davis, Andrew M. , Skinner, Jonathan R. , Kannankeril, Prince J. , Haugaa, Kristina H. , Leenhardt, Antoine , Werf, Christian van der

Mayo Clinic

Circulation | December 7, 2021 | Volume: 145 | Issue: 5 | Pages: 333-344

10.1161/circulationaha.121.056018 | PMID 34874747 Get It

Background: Symptomatic children with catecholaminergic polymorphic ventricular tachycardia (CPVT) are at risk for recurrent arrhythmic events. β-Blockers decrease this risk, but studies comparing individual β-blockers in sizeable cohorts are lacking. We aimed to assess the association between risk for arrhythmic events and type of β-blocker in a large cohort of symptomatic children with CPVT. Methods: From 2 international registries of patients with CPVT, RYR2 variant–carrying symptomatic children (defined as syncope or sudden cardiac arrest before β-blocker initiation and age at start of β-blocker therapy <18 years), treated with a β-blocker were included. Cox regression analyses with time-dependent covariates for β-blockers and potential confounders were used to assess the hazard ratio (HR). The primary outcome was the first occurrence of sudden cardiac death, sudden cardiac arrest, appropriate implantable cardioverter-defibrillator shock, or syncope. The secondary outcome was the first occurrence of any of the primary outcomes except syncope. Results: We included 329 patients (median age at diagnosis, 12 [interquartile range, 7–15] years, 35% females). Ninety-nine (30.1%) patients experienced the primary outcome and 74 (22.5%) experienced the secondary outcome during a median follow-up of 6.7 (interquartile range, 2.8–12.5) years. Two-hundred sixteen patients (66.0%) used a nonselective β-blocker (predominantly nadolol [n=140] or propranolol [n=70]) and 111 (33.7%) used a β1-selective β-blocker (predominantly atenolol [n=51], metoprolol [n=33], or bisoprolol [n=19]) as initial β-blocker. Baseline characteristics did not differ. The HRs for both the primary and secondary outcomes were higher for β1-selective compared with nonselective β-blockers (HR, 2.04 [95% CI, 1.31–3.17]; and HR, 1.99 [95% CI, 1.20–3.30], respectively). When assessed separately, the HR for the primary outcome was higher for atenolol (HR, 2.68 [95% CI, 1.44–4.99]), bisoprolol (HR, 3.24 [95% CI, 1.47–7.18]), and metoprolol (HR, 2.18 [95% CI, 1.08–4.40]) compared with nadolol, but did not differ from propranolol. The HR of the secondary outcome was only higher in atenolol compared with nadolol (HR, 2.68 [95% CI, 1.30–5.55]). Conclusions: β1-selective β-blockers were associated with a significantly higher risk for arrhythmic events in symptomatic children with CPVT compared with nonselective β-blockers, specifically nadolol. Nadolol, or propranolol if nadolol is unavailable, should be the preferred β-blocker for treating symptomatic children with CPVT.
Management of lytic bone disease in lymphoplasmacytic lymphoma: A case report and review of the literature
Baksh, Mizba , Jiang, Liuyan , Bhatia, Unnati , Alegria, Victoria R., Sher, Taimur , Chanan‐Khan, Asher , Ailawadhi, Sikander , Parrondo, Ricardo , Alegria, Victoria, Chanan-Khan, Asher, Ailawadhi, Sikander , Parrondo, Ricardo D , Baksh, Mizba , Roy, Vivek

Mayo Clinic

Clinical Case Reports | December 7, 2021 | Volume: 9 | Issue: 12 | Pages: No page available

10.1002/ccr3.5181 | PMID 34934497 Get It

AbstractWaldenström macroglobulinemia (WM)/lymphoplasmacytic lymphoma (LPL) is often differentiated from myeloma based on the presence of lytic bone lesions (LBL). However, WM/LPL can present with LBL, and management is poorly understood. We describe a case of an 81‐year‐old woman with LPL who presented with LBL and was successfully treated with chemoimmunotherapy.
Microglial TREM2 in amyotrophic lateral sclerosis
Xie, Manling , Zhao, Shunyi , Bosco, Dale B. , Nguyen, Aivi T. , Wu, Long‐Jun , Wu, Long-Jun , Nguyen, Aivi T , Xie, Manling , Zhao, Shunyi

Mayo Clinic

Developmental Neurobiology | December 7, 2021 | Volume: 82 | Issue: 1 | Pages: 125-137

10.1002/dneu.22864 | PMID 34874625 Get It

AbstractAmyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's disease, is an aggressive motor neuron degenerative disease characterized by selective loss of both upper and lower motor neurons. The mechanisms underlying disease initiation and progression are poorly understood. The involvement of nonmotor neuraxis emphasizes the contribution of glial cells in disease progress. Microglia comprise a unique subset of glial cells and are the principal immune cells in the central nervous system (CNS). Triggering receptor expressed on myeloid cell 2 (TREM2) is a surface receptor that, within the CNS, is exclusively expressed on microglia and plays crucial roles in microglial proliferation, migration, activation, metabolism, and phagocytosis. Genetic evidence has linked TREM2 to neurodegenerative diseases including ALS, but its function in ALS pathogenesis is largely unknown. In this review, we summarize how microglial activation, with a specific focus on TREM2 function, affects ALS progression clinically and experimentally. Understanding microglial TREM2 function will help pinpoint the molecular target for ALS treatment.
Anticachectic regulator analysis reveals Perp-dependent antitumorigenic properties of 3-methyladenine in pancreatic cancer
Arneson‐Wissink, Paige C. , Schmitt, R. , Cho, Dong Seong , Ducharme, Alexandra M. , Hogenson, Tara L. , Krueger, Eugene W. , Zhang, Lizhi , Fernández-Zapico, Martín E. , Schmitt, Rebecca E , Ducharme, Alexandra , Dasgupta, Aneesha , Bamlet, William R. , Razidlo, Gina L. , Doles, Jason D.

Mayo Clinic

JCI Insight | December 7, 2021 | Volume: 7 | Issue: 2 | Pages: No page available

10.1172/jci.insight.153842 | PMID 34874916 Get It

Approximately 80% of pancreatic cancer patients suffer from cachexia, and one-third die due to cachexia-related complications such as respiratory failure and cardiac arrest. Although there has been considerable research into cachexia mechanisms and interventions, there are, to date, no FDA-approved therapies. A major contributing factor for the lack of therapy options could be the failure of animal models to accurately recapitulate the human condition. In this study, we generated an aged model of pancreatic cancer cachexia to compare cachexia progression in young versus aged tumor-bearing mice. Comparative skeletal muscle transcriptome analyses identified 3-methyladenine (3-MA) as a candidate antiwasting compound. In vitro analyses confirmed antiwasting capacity, while in vivo analysis revealed potent antitumor effects. Transcriptome analyses of 3-MA–treated tumor cells implicated Perp as a 3-MA target gene. We subsequently (a) observed significantly higher expression of Perp in cancer cell lines compared with control cells, (b) noted a survival disadvantage associated with elevated Perp , and (c) found that 3-MA–associated Perp reduction inhibited tumor cell growth. Finally, we have provided in vivo evidence that survival benefits conferred by 3-MA administration are independent of its effect on tumor progression. Taken together, we report a mechanism linking 3-MA to Perp inhibition, and we further implicate Perp as a tumor-promoting factor in pancreatic cancer.
Automated Segmentation of Kidney Cortex and Medulla in CT Images: A Multisite Evaluation Study
Korfiatis, Panagiotis , Đenić, Aleksandar , Edwards, Marie E., Gregory, Adriana , Wright, Darryl, Augustine, Joshua J. , Rule, Andrew D. , Kline, Timothy L. , Gregory, Adriana V, Wright, Darryl E, Mullan, Aidan, Rule, Andrew D , Denic, Aleksandar , Mullan, Aidan F. , Augustine, Joshua

Mayo Clinic

Journal of the American Society of Nephrology | December 7, 2021 | Volume: 33 | Issue: 2 | Pages: 420-430

10.1681/asn.2021030404 | PMID 34876489 Get It

Background In kidney transplantation, a contrast CT scan is obtained in the donor candidate to detect subclinical pathology in the kidney. Recent work from the Aging Kidney Anatomy study has characterized kidney, cortex, and medulla volumes using a manual image-processing tool. However, this technique is time consuming and impractical for clinical care, and thus, these measurements are not obtained during donor evaluations. This study proposes a fully automated segmentation approach for measuring kidney, cortex, and medulla volumes. Methods A total of 1930 contrast-enhanced CT exams with reference standard manual segmentations from one institution were used to develop the algorithm. A convolutional neural network model was trained ( n =1238) and validated ( n =306), and then evaluated in a hold-out test set of reference standard segmentations ( n =386). After the initial evaluation, the algorithm was further tested on datasets originating from two external sites ( n =1226). Results The automated model was found to perform on par with manual segmentation, with errors similar to interobserver variability with manual segmentation. Compared with the reference standard, the automated approach achieved a Dice similarity metric of 0.94 (right cortex), 0.90 (right medulla), 0.94 (left cortex), and 0.90 (left medulla) in the test set. Similar performance was observed when the algorithm was applied on the two external datasets. Conclusions A fully automated approach for measuring cortex and medullary volumes in CT images of the kidneys has been established. This method may prove useful for a wide range of clinical applications.